Vext Science Past Earnings Performance
Past criteria checks 0/6
Vext Science's earnings have been declining at an average annual rate of -10.2%, while the Pharmaceuticals industry saw earnings growing at 45.6% annually. Revenues have been growing at an average rate of 9.5% per year.
Key information
-10.2%
Earnings growth rate
-9.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 9.5% |
| Return on equity | -8.9% |
| Net Margin | -22.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
It's Down 26% But Vext Science, Inc. (CSE:VEXT) Could Be Riskier Than It Looks
Oct 24
Take Care Before Jumping Onto Vext Science, Inc. (CSE:VEXT) Even Though It's 30% Cheaper
Jun 18There Is A Reason Vext Science, Inc.'s (CSE:VEXT) Price Is Undemanding
Jan 16Is Now The Time To Put Vext Science (CSE:VEXT) On Your Watchlist?
Sep 29Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?
Aug 16Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?
Jan 17Shareholders May Be More Conservative With Vext Science, Inc.'s (CSE:VEXT) CEO Compensation For Now
Dec 09We Think Vext Science (CSE:VEXT) Can Stay On Top Of Its Debt
Sep 29Vext Science (CSE:VEXT) Seems To Use Debt Quite Sensibly
Apr 29Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?
Nov 15Is Vext Science (CSE:VEXT) A Risky Investment?
Jul 15Weak Statutory Earnings May Not Tell The Whole Story For Vext Science (CSE:VEXT)
Apr 25Based On Its ROE, Is Vext Science, Inc. (CSE:VEXT) A High Quality Stock?
Jan 15Revenue & Expenses Breakdown
How Vext Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 34 | -8 | 16 | 0 |
| 30 Jun 24 | 33 | -7 | 16 | 0 |
| 31 Mar 24 | 34 | -2 | 14 | 0 |
| 31 Dec 23 | 35 | 4 | 14 | 0 |
| 30 Sep 23 | 35 | 5 | 8 | 0 |
| 30 Jun 23 | 34 | 7 | 8 | 0 |
| 31 Mar 23 | 34 | 9 | 10 | 0 |
| 31 Dec 22 | 35 | 11 | 10 | 0 |
| 30 Sep 22 | 37 | 6 | 9 | 0 |
| 30 Jun 22 | 38 | 6 | 7 | 0 |
| 31 Mar 22 | 39 | 6 | 7 | 0 |
| 31 Dec 21 | 37 | 5 | 6 | 0 |
| 30 Sep 21 | 34 | 5 | 6 | 0 |
| 30 Jun 21 | 33 | 5 | 6 | 0 |
| 31 Mar 21 | 30 | 4 | 5 | 0 |
| 31 Dec 20 | 25 | 2 | 5 | 0 |
| 30 Sep 20 | 22 | 0 | 6 | 0 |
| 30 Jun 20 | 20 | 0 | 6 | 0 |
| 31 Mar 20 | 20 | 0 | 6 | 0 |
| 31 Dec 19 | 22 | 3 | 5 | 0 |
| 30 Sep 19 | 23 | 4 | 4 | 0 |
| 30 Jun 19 | 23 | 5 | 4 | 0 |
| 31 Mar 19 | 21 | 4 | 3 | 0 |
| 31 Dec 18 | 18 | 4 | 3 | 0 |
| 31 Dec 17 | 15 | 4 | 2 | 0 |
Quality Earnings: VEXT is currently unprofitable.
Growing Profit Margin: VEXT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VEXT is unprofitable, and losses have increased over the past 5 years at a rate of 10.2% per year.
Accelerating Growth: Unable to compare VEXT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VEXT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: VEXT has a negative Return on Equity (-8.94%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 22:12 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vext Science, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matt Bottomley | Canaccord Genuity |
| Shaan Mir | Canaccord Genuity |
| Neal Gilmer | Haywood Securities Inc. |